SCINTIX radiation therapy for solid tumors using PET guidance
Part of Cancer clinical trials.
This trial tests a new way to deliver radiation called SCINTIX that uses PET scans to target tumors more precisely. It is for people with certain solid tumors that are not in the bone or lungs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 21 or older.
- You have a confirmed cancer (by biopsy) that has spread or is the primary tumor, and it is located in soft tissues (not bone or lung).
- The target tumor must be between 2 cm and 5 cm in size and show high activity on a PET scan (SUVmax of 6 or more).
- You must be able to have 3 to 5 radiation treatments (stereotactic body radiation).
- You need to be in fair general health (ECOG score 0-3) and not pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether using a PET scan to guide focused radiation (SBRT) can control a small number of cancer spots that are starting to grow despite prior treatment. It may help patients avoid wider radiation by targeting only the limited progressing areas.
This early (Phase 1) study uses a special PET scan to measure how your immune system responds after stereotactic body radiation therapy (SBRT). The goal is to see whether the scan result can serve as a marker of immune response, which may help future treatment planning.
This trial tests a new imaging agent (18F-TRX) to see if it can better detect cancer spread in people with advanced solid tumors. It is designed for patients with specific cancers like high-grade brain tumors, advanced kidney cancer, or prostate cancer that has stopped responding to hormone therapy.
This early-phase study tests the safety of a targeted radiation treatment (212Pb-Pentixather) in people whose scans show a specific marker called CXCR4. It may help by delivering radiation to lesions that have this marker, but the main goal here is to check safety and dosing.
This trial tests a new type of PET scan (a special imaging test) called 89Zr-s-C1 to help detect and monitor solid tumors like melanoma, gastric cancer, or colorectal cancer. The scan may help doctors see tumors more clearly and track whether treatment is working.
This trial is testing a new imaging agent called RT01-89Zr to see if it can help detect solid tumors during PET/CT scans. It involves an injection of the agent followed by imaging, and may offer a more targeted way to visualize tumors.
Hear when a new Thoracic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.